Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Fu Haixia, Dr.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07662525
- Record updated
- 23 June 2026
- Original description
This is a prospective, single-arm, open-lable, single-center study and we aimed to determine whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim could induce sustained response off-treatment (SRoT) in adult patients with ITP following CS failure.Read full original descriptionShow less
Atorvastatin Combined With N-Acetyl-L-Cysteine Plus Romiplostim for Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia
This is a prospective, single-arm, open-lable, single-center study and we aimed to determine whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim could induce sustained response off-treatment (SRoT) in adult patients with ITP following CS failure.
Inclusion: Diagnosed with primary ITP; Aged ≥18 years; Patients with treatment failure or relapse after first-line corticosteriod therapy for ITP; Platelet count <30×10⁹/L.
Exclusion: Presence of active malignant tumors; Active HBV, HCV or HIV infection; Active infection requiring systematic treatment; Leukemia, myelodysplastic syndrome, aplastic anemia, myelofibrosis or other hematological disorders that may cause thrombocytopenia; History or presence of myocardial infarction, unstable ischemic heart disease, stroke, or NYHA Class IV heart failure; AST > 2 times the upper limit of normal (ULN), ALT > 2×ULN, or TBIL ≥ 1.5×ULN; eGFR < 50 mL/min/1.73m²; Pregnant or lactating women, and who were possibly pregnant, planning to become pregnant, or who had partners planning to become pregnant; Any other subjects deemed ineligible for enrollment by the investigator.